Adjunctive Dapagliflozin Improves Glycemic Control in T1D
Dapagliflozin, when used as adjunct treatment to insulin, improves glycemic control in patients with type 1 diabetes.
For youth with type 1 diabetes, disordered eating behaviors are associated with higher hemoglobin A1c but not with measures of glycemic variability.
Transcription factor 7 like 2 genetic variants contribute to phenotypic heterogeneity of type 1 diabetes.
Patients with diabetes had higher rates for all 19 infection categories with the highest incidence rate ratios seen for bone and joint infections, sepsis, and cellulitis.